Safety of enteral naloxone and i.v. neostigmine when used to relieve constipation

American Journal of Health-System Pharmacy

Volumn 60, Issue 12, 2003, Pages 1264-1267

  Thomas, Michael C ^a   Erstad, Brian L ^b  

^a MUNSON MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; CHOLINESTERASE INHIBITOR; DOPAMINE; LORAZEPAM; MORPHINE SULFATE; NALOXONE; NEOSTIGMINE METHYL SULFATE; PANCURONIUM; PROPOFOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; NARCOTIC ANTAGONIST; NEOSTIGMINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANXIETY; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CONSTIPATION; DEFECATION; DIZZINESS; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; FEMALE; FLATULENCE; HEART RATE; HUMAN; HYPERTENSION; INTESTINE ABSORPTION; INTESTINE NECROSIS; INTESTINE PERFORATION; ISCHEMIC COLITIS; MALE; NAUSEA; PRIORITY JOURNAL; SALIVATION DISORDER; SIDE EFFECT; SPUTUM; SYSTOLIC BLOOD PRESSURE; TREMOR; VOMITING; WITHDRAWAL SYNDROME; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COLIC; COMPARATIVE STUDY; DIGESTIVE TRACT INTUBATION; HEART ARRHYTHMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RECTAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADOLESCENT; ADULT; AGED; ARRHYTHMIA; COLIC; CONSTIPATION; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTENSION; HYPOTENSION; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTUBATION, GASTROINTESTINAL; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; NAUSEA; NEOSTIGMINE; PARASYMPATHOMIMETICS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0141832647     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.12.1264     Document Type: Article

References (10)

1. Friedman JD, Dello Buono FA. Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann Pharmacother. 2001; 35:85-91.
2. Kaufman PN, Krevsky B, Malmud LS et al. Role of opioid receptors in the regulation of colonic transit. Gastroenterology. 1988; 94:1351-6.
3. Sykes NP. Oral naloxone in opioid-associated constipation. Lancet. 1991; 337:1475. Letter.
4. Schang JC, Devroede G. Beneficial effects of naloxone in a patient with intestinal pseudoobstruction. Am J Gastroenterol. 1985; 80:407-11.
5. Culpepper-Morgan JA, Inturissi C, Portenoy R et al. Oral naloxone treatment of narcotic induced constipation: dose response. NIDA Res Monogr. 1989; 95:399-400.
6. Culpepper-Morgan JA, Inturrisi CE, Portenoy RK et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther. 1992; 52:90-5.
7. Meissner W, Schmidt U, Hartman M et al. Oral naloxone reverses opioid-associated constipation. Pain. 2000; 84: 105-9.
8. Robinson BA, Johansson L, Shaw J. Oral naloxone in opioid-associated constipation. Lancet. 1991; 338:581-2.
9. Van der Spoel JI, Oudemans-van Straaten HM, Stoutenbeek CP et al. Neostigmine resolves critical illness-related colonic ileus in intensive care patients with multiple organ failure - a prospective, double-blind, placebo-controlled trial. Intensive Care Med. 2001; 27:822-7.
10. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med. 1999; 341:137-41.